Didi Tao
Department of Pediatrics, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
*Corresponding author: Didi Tao
Abstract
Objective: To compare the effects of multiple subcutaneous insulin injection (MDI) and continuous subcutaneous insulin infusion (CSII) on the glycemic control effect in children with type 1 diabetes mellitus (T1DM). Methods: In this study, 70 T1DM children admitted from March 2022 to June 2024 were included as the study sample. The children were divided into Group A and Group B, with 35 patients in each group. CSII mode was adopted in group A and MDI mode in Group B. The effects of glycemic control [glycosylated hemoglobin (HbAlc), fasting blood glucose (FPG), 2h postprandial blood glucose (2 hPG), insulin dosage, blood glucose recovery time, and incidence of hypoglycemia were compared. Results: After 3 months of treatment, Hb Alc, FPG, and 2 hPG levels in both groups decreased compared with before treatment (P <0.05), and Group A was lower than Group B (P <0.05). Insulin dosage in Group A was less than that in Group B (P <0.05), and the recovery time of blood glucose in Group A was shorter than that in Group B (P <0.05). The incidence of hypoglycemia in Group A was lower than that in Group B (P <0.05). Conclusion: Compared with MDI, CSII is more beneficial to help children with T1DM control blood glucose levels, reduce the amount of insulin, shorten the time of blood glucose recovery, and reduce the incidence of hypoglycemia.
References
[1] Alassaf A, Gharaibeh L, Odeh R, et al. Predictors of glycemic control in children and adolescents with type 1 diabetes at 12 months after diagnosis. Pediatr Diabetes. 2022;23(6):729-735.
[2] Forlenza GP, McVean J, Beck RW, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023;329(12):990-999.
[3] Barlas T, Yalcin MM, Coskun M, et al. Evaluation of Lipohypertrophy in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injections or Continuous Subcutaneous Insulin Infusion. Endocr Pract. 2023;29(2):119-126.
[4] Gong Y, Wei T, Liu Y, et al. Continuous subcutaneous insulin infusion versus multiple daily injection therapy in pregnant women with type 1 diabetes. J Diabetes. 2024;16(5):e13558.
[5] Wang LN, Feng XY, Zhang LJ, et al. Clinical study of continuous subcutaneous insulin infusion in children with type I diabetes mellitus. Int J Pediatr. 2023;50(2):135-140.
[6] Diabetes Branch of Chinese Medical Association, Endocrinology and Metabolism Physician Branch of Chinese Medical Doctor Association, Endocrinology Branch of Chinese Medical Association, et al. Guidelines for the Diagnosis and Treatment of Type 1 Diabetes in China (2021 edition). Chin Diabetes J. 2022;14(11):1143-1250.
[7] Yang HX, Leng XF, Hu CC, et al. Observation of the efficacy of insulin pump therapy in children with long-term follow-up. Chin J Contemp Pediatr. 2021;23(2):116-120.
[8] Liu YF, Chen TL, Zheng ZS. Factors influencing the effect of long-term continuous subcutaneous insulin infusion in children with type 1 diabetes. Chin Contemp Med. 2024;31(29):75-78.
[9] Lang Q, Cao YL. The clinical effect of different insulin injections in pediatric type 1 diabetes. China Pract Med. 2023;18(1):28-31.
[10] Lu MJ. Analysis of the sugar control effect of continuous subcutaneous infusion of insulin pump for type 2 diabetes mellitus. Diabetes New World. 2024;27(12):97-100.
How to cite this paper
To Compare the Effects of Multiple Subcutaneous Insulin Injections with Continuous Subcutaneous Insulin Infusion on the Glycemic Control Effect in Children with T1DM
How to cite this paper: Didi Tao. (2025) To Compare the Effects of Multiple Subcutaneous Insulin Injections with Continuous Subcutaneous Insulin Infusion on the Glycemic Control Effect in Children with T1DM. International Journal of Clinical and Experimental Medicine Research, 9(5), 509-512.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.09.003